ArticleMedical physics2026
A tandem reinforcement learning framework for localized prostate cancer treatment planning and machine parameter optimization.
Article in Medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundVolumetric modulated arc therapy (VMAT) machine parameter optimization (MPO) is a complex, high-dimensional problem typically solved with inverse planning solutions that are both temporally and computationally expensive. While machine learning techniques have been explored to automate this process, they often supplement rather than replace conventional optimizers and are fundamentally limited by the quality and diversity of training data. Reinforcement learning (RL) offers a promising alternative, finding optimal strategies through trial-and-error by maximizing a narrowly tailored reward function, which can potentially discover novel solutions beyond mimicking features present in existing plans. PURPOSE: The purpose of this study was to develop and validate a deep reinforcement learning-based VMAT MPO algorithm capable of automatically generating clinically comparable treatment plans for prostate cancer that meet machine constraints, entirely independent of a commercial treatment planning system (TPS) optimizer.
methodsA dataset comprised of 100 prostate cancer patients planned using the criteria from PACE-B SBRT arm serve as the basis for network training using a 70-10-20 training/validation/testing split. An RL framework using a Proximal Policy Optimization (PPO) algorithm was developed to train two tandem convolutional neural networks that sequentially optimize multi-leaf collimator (MLC) positions and monitor units (MUs) using current dose, contoured structure masks, and current machine parameters as inputs. Training was designed to predict MLC positions and MUs that maximize a dose-volume histogram (DVH)-based reward function tailored to prioritize meeting clinical objectives. The fully trained networks were executed on a test set of 20 patients and compared to reference plans optimized with a commercial TPS.
resultsThe RL algorithm generated plans in an average of 6.3 ± 4.7 s. Compared to the reference plans, the RL-generated plans demonstrated improved sparing for both the bladder and rectum across their respective dosimetric endpoints. When normalizing to 95% coverage, the RL generated plans resulted in a statistically significant increase in the PTV
conclusionsWe successfully developed and validated a deep RL framework for VMAT MPO. The algorithm rapidly generates VMAT prostate cancer treatment plans that meet clinical constraints and are dosimetrically comparable to manually optimized plans without the use of a commercial TPS optimizer. This work demonstrates the feasibility of RL as a tool to fully automate the VMAT planning process, offering the potential to decrease planning times while maintaining plan quality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.